-
In the wake of a first-of-its-kind settlement regarding the discharge of a homeless woman by a Kaiser Permanente hospital in Southern California, indications are that the disturbing issues it aims to address are far from unique.
-
A two-pronged initiative under way at Sutter Medical Center in Sacramento, CA, aims to provide interim housing for homeless patients who need home support services or assistance with medications as well as reduce the use of the hospital emergency departments (EDs) for primary care among homeless patients.
-
Beginning July 2, hospitals must begin a new process of notifying Medicare beneficiaries of their discharge appeal rights.
-
At Memorial Hermann Texas Medical Center in Houston, quality professionals are well aware of the importance of getting an outside perspective. "When you are in the midst of the forest, you can't see some of the processes that have become a habit to you," says Angela Lenox, the hospital's peer review manager.
-
It's not uncommon for hospitals to receive requirements for improvements (RFIs) after a Joint Commission survey. What is surprising is that in May, Boston-based Massachusetts General Hospital chose to share this information publicly — not just its accreditation status, but its complete survey results.
-
Joint Commission standards require the organized medical staff oversee the quality of care, treatment, and services rendered by physicians and other licensed independent practitioners. This includes monitoring the quality of services provided by hospital-based practitioners such as radiologists and pathologists.
-
-
Now that IRBs have both the final guidance on unanticipated problems and adverse events from the Office for Human Research Protections (OHRP) of Rockville, MD, and the draft guidance from the Food and Drug Administration (FDA), their duties in handling these issues should be clear, right?
-
In April, 2007, the Food and Drug Administration (FDA) issued its draft "Guidance for Clinical Investigators, Sponsors, and IRBs; Adverse Event Reporting Improving Human Subject Protection."
-
When IRB members weigh risks and benefits of an oncology clinical trial, they need to put risks and benefits in perspective for this particular population, or else they'll err by being too cautious, an expert suggests.
